Medicare Patients' Psoriasis, PsA Drug Costs Remain High Medicare Patients' Psoriasis, PsA Drug Costs Remain High
Coverage of and access to biologics for psoriasis and psoriatic arthritis are compromised by out-of-pocket payments and prior authorization requirements.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 16, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Cannabidiol Found No Better Than Placebo for Hand Arthritis Pain Cannabidiol Found No Better Than Placebo for Hand Arthritis Pain
Patients with hand osteoarthritis or psoriatic arthritis who used cannabidiol as an add-on analgesic had results similar to those of placebo.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 16, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Consider Itch and Joint Pain in Pediatric Psoriasis Patients Consider Itch and Joint Pain in Pediatric Psoriasis Patients
About 1% of pediatric psoriasis patients have psoriatic arthritis, which is much less common than in adults is"but important to find and manage."Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 3, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Treatment With Guselkumab Resolves Enthesitis in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 28, 2021 Category: Orthopaedics Tags: Perspective Source Type: news

Psoriatic Arthritis Worsens QoL in Patients With Psoriasis
Individuals with psoriasis/PsA have decreased ability to participate in social roles and activities, more depression symptoms (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - August 25, 2021 Category: Psychiatry Tags: Dermatology, Family Medicine, Internal Medicine, Psychiatry, Rheumatology, Journal, Source Type: news

Psoriatic Arthritis Worsens QoL in Patients With Psoriasis
WEDNESDAY, Aug. 25, 2021 -- People with psoriasis/psoriatic arthritis (PsA) have a decreased ability to participate in social roles and activities and more depressive symptoms than those with psoriasis alone, according to a research letter published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 25, 2021 Category: Pharmaceuticals Source Type: news

Physicians Question Future of TNF Inhibitors for Psoriasis, PsA Physicians Question Future of TNF Inhibitors for Psoriasis, PsA
Two dermatologists and two rheumatologists debate the merits of using IL-17 and IL-23 inhibitors ahead of TNF inhibitors for the treatment of psoriasis and psoriatic arthritis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 9, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Papers on COVID-19 in Psoriasis, Psoriatic Arthritis Carry Risk for Bias
WEDNESDAY, Aug. 4, 2021 -- Published papers addressing the risk and outcomes of COVID-19 in patients with psoriasis and psoriatic arthritis receiving biologic therapies have a high risk for bias, according to a study published online Aug. 4 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 4, 2021 Category: Pharmaceuticals Source Type: news

How Do You Get a Psoriatic Arthritis Diagnosis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 26, 2021 Category: General Medicine Source Type: news

What Is the Life Expectancy of Someone With Psoriatic Arthritis?
Title: What Is the Life Expectancy of Someone With Psoriatic Arthritis?Category: Diseases and ConditionsCreated: 7/23/2021 12:00:00 AMLast Editorial Review: 7/23/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 23, 2021 Category: Rheumatology Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

How Do You Describe Psoriatic Arthritis Pain
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 21, 2021 Category: General Medicine Source Type: news

Does Psoriatic Arthritis Affect Elbows
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 21, 2021 Category: General Medicine Source Type: news

What Is the Safest Drug for Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 21, 2021 Category: General Medicine Source Type: news

CBD for Psoriasis and Psoriatic Arthritis: What You Should Know
CBD is growing in popularity, and there are many over-the-counter skin products infused with CBD. While CBD can provide some pain relief to psoriasis and psoriatic arthritis, experts say there needs to be more research. (Source: WebMD Health)
Source: WebMD Health - July 20, 2021 Category: Consumer Health News Source Type: news

What Is the Life Expectancy of Psoriatic Arthritis
What Is the Life Expectancy of Someone with Psoriatic Arthritis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 19, 2021 Category: General Medicine Source Type: news

What Are the Five Types of Psoriatic Arthritis?
Title: What Are the Five Types of Psoriatic Arthritis?Category: Diseases and ConditionsCreated: 7/13/2021 12:00:00 AMLast Editorial Review: 7/13/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 13, 2021 Category: Rheumatology Source Type: news

How Is Psoriatic Arthritis Diagnosed?
Title: How Is Psoriatic Arthritis Diagnosed?Category: Diseases and ConditionsCreated: 7/12/2021 12:00:00 AMLast Editorial Review: 7/12/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 12, 2021 Category: Rheumatology Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Tips for Managing Psoriatic Arthritis
Medical treatment for your psoriatic arthritis (PsA) is essential for managing symptoms and protecting your joints. Add these daily practices to help with joint health and keep flare-ups at bay. (Source: WebMD Health)
Source: WebMD Health - July 8, 2021 Category: Consumer Health News Source Type: news

Inflammation at IP Thumb Joint Common in Psoriatic Arthritis
THURSDAY, July 1, 2021 -- Patients with psoriatic arthritis (PsA) more often have inflammation at the interphalangeal (IP) joint of the thumb compared to those with undifferentiated inflammatory arthritis (UIA), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 1, 2021 Category: Pharmaceuticals Source Type: news

Psoriatic Arthritis and Rheumatoid Arthritis Have Comparable Impact on Hand Strength, Fine Motor Skills, and Function
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - June 18, 2021 Category: Orthopaedics Tags: Trends and Innovations Source Type: news

Secukinumab Provides Clinical Benefit for JIA Subtypes Secukinumab Provides Clinical Benefit for JIA Subtypes
Phase 3 trial shows secukinumab is effective for enthesitis-related arthritis and juvenile psoriatic arthritis in children.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 16, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Arthritis symptoms: Four 'weird and unusual' signs of arthritis pain you might be missing
ARTHRITIS symptoms usually include joint pain and inflammation, but the signs could also be more subtle. These are the four most common "weird and unusual" symptoms of psoriatic arthritis that you might be missing - should you speak to a doctor? (Source: Daily Express - Health)
Source: Daily Express - Health - June 16, 2021 Category: Consumer Health News Source Type: news

What Does a Psoriatic Arthritis Rash Look Like
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 10, 2021 Category: General Medicine Source Type: news

What Are the Five Types of Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 10, 2021 Category: General Medicine Source Type: news

What Foods Make Psoriatic Arthritis Worse
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 8, 2021 Category: General Medicine Source Type: news

What Is the Best Treatment for Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 7, 2021 Category: General Medicine Source Type: news

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fecal Transplantation Safe but Ineffective in PsA Trial Fecal Transplantation Safe but Ineffective in PsA Trial
A trial found fecal microbiota transplantation in psoriatic arthritis inferior to sham but safe, and investigators said it's worthy of future study.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 8, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMF...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

What Can Mimic Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 20, 2021 Category: General Medicine Source Type: news

Arthritis symptoms: Nail changes are a ‘strong predictor’ of arthritis - what to look for
Arthritis is a common condition that causes pain and inflammation in a joint. Arthritis comes in many forms and nail changes are predictive of a type of arthritis called psoriatic arthritis. (Source: Daily Express - Health)
Source: Daily Express - Health - April 6, 2021 Category: Consumer Health News Source Type: news

Will Psoriatic Arthritis Cripple Me?
Title: Will Psoriatic Arthritis Cripple Me?Category: Diseases and ConditionsCreated: 4/5/2021 12:00:00 AMLast Editorial Review: 4/5/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 5, 2021 Category: Rheumatology Source Type: news

Upadacitinib Beats Placebo for Psoriatic Arthritis
WEDNESDAY, March 31, 2021 -- For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine. Iain... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2021 Category: Pharmaceuticals Source Type: news

Experts Highlight Recent Breakthroughs in Psoriatic Arthritis Experts Highlight Recent Breakthroughs in Psoriatic Arthritis
An analysis by Alexis R. Ogdie, MD, of apremilast data from the CORRONA Registry was among several recent highlights in psoriatic arthritis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 31, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Yes or No: The Future of Rheumatology Is Sub-Subspecialization Yes or No: The Future of Rheumatology Is Sub-Subspecialization
It makes little sense for some rheumatologists to declare they're only going to see patients with psoriatic arthritis, or gout, or lupus.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients
Patients taking methotrexate for psoriasis or psoriatic arthritis were at a higher risk of developing liver disease than were patients with rheumatoid arthritis on methotrexate.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - February 26, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

Treatment Persistence of Biologics in Psoriatic Arthritis Treatment Persistence of Biologics in Psoriatic Arthritis
A better understanding of biologic treatment persistence in psoriatic arthritis patients could help guide treatment decisions.Arthritis Research & Therapy (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 25, 2021 Category: Orthopaedics Tags: Rheumatology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Cardiorespiratory Fitness Linked to Psoriasis, Psoriatic Arthritis
FRIDAY, Jan. 15, 2021 -- Low cardiovascular fitness in late adolescence is associated with an increased risk for incident psoriasis and psoriatic arthritis among men, according to a study published online Jan. 11 in PLOS ONE. Marta Laskowski, from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 15, 2021 Category: Pharmaceuticals Source Type: news

Osteoporosis Prevalence in PsA Similar to General Population Osteoporosis Prevalence in PsA Similar to General Population
Previous research suggested a possible link between psoriatic arthritis and osteoporosis or osteopenia. However, no cohort studies appear to have examined this association.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - January 7, 2021 Category: Primary Care Tags: Rheumatology News Source Type: news

Skin Gene Expression May Explain PsA Treatment Responses Skin Gene Expression May Explain PsA Treatment Responses
Differences in gene expression between the skin and synovial tissues of people with psoriatic arthritis could explain why treatments targeting proinflammatory mechanisms don't improve joint symptoms.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 15, 2020 Category: Internal Medicine Tags: Rheumatology News Source Type: news

CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoi... Biopharmaceuticals, Regulatory AbbVie, RINVOQ, upadacitinib, psoriatic arthritis, ankylosing spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2020 Category: Pharmaceuticals Source Type: news

ACR Convergence: Psoriatic Arthritis ACR Convergence: Psoriatic Arthritis
Dr Saakshi Khattri reviews key abstracts about psoriatic arthritis from the annual ACR meeting, including a tool for early detection and a study showing dactylitis may signal an aggressive phenotype.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Increased falls risk in people with psoriatic arthritis-related foot problems: a novel finding - Carter K, Walmsley S, Oliffe M, Hassett G, Turner ADE.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - November 23, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3 Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
The oral JAK inhibitor was significantly more effective than placebo at primary and secondary endpoints. Safety risks were comparable to those seen in the treatment of rheumatoid and psoriatic arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news